- Clover Health press release ( NASDAQ: CLOV ): Q4 net loss of $84M.
- Revenue of $898.8M (+108.1% Y/Y).
- Q4 2022 Insurance MCR of 92.4% and FY 2022 Insurance MCR of 91.8%
-
For full-year 2023, Clover Health is providing its guidance as follows:
- Insurance revenue is expected to be in the range of $1.15 billion to $1.20 billion in 2023, a growth rate of 6% - 11% as compared to full year 2022 Insurance revenue.
- Insurance MCR is expected to be in the range of 89% - 91% in 2023.
- Non-Insurance revenue is expected to be in the range of $0.75 billion to $0.80 billion in 2023.
- Non-Insurance MCR is expected to be in the range of 98% - 100% in 2023.
- Adjusted SG&A (non-GAAP) (1) is expected to be between $315 million and $325 million.
- Adjusted EBITDA (non-GAAP) (1) is expected to be between ($155 million) and ($205 million).
For further details see:
Clover Health reports Q4 results